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Abstract
Background: Vitamin D deficiency is common and predisposes to many serious diseases, yet often
goes unrecognized.
Findings: We describe a case of severe vitamin D deficiency with osteomalacia in a patient
resident in a psychiatric hospital for more than 35 years, and discuss causes and complications. We
assayed the serum 25-hydroxyvitamin D levels of all patients under our care on one old-age
psychiatry rehabilitation unit. Ten of twelve (83%) of patients had vitamin D deficiency, and 92%
had suboptimal vitamin D levels. Vitamin D status was strongly predicted by dietary
supplementation. Of those not on vitamin D supplements, 100% had vitamin D deficiency, with
vitamin D levels significantly below those of historical controls. Age, sex, and duration of admission
did not predict vitamin D status in this group.
Conclusion: We advocate vitamin D screening in all patients admitted to psychogeriatric units,
and discuss treatment options given the current problems affecting high-dose vitamin D supply to
the United Kingdom.
Background
Vitamin D deficiency is so common as to represent a
major public health problem, particularly in the elderly
[1], yet it often goes unrecognized. We report on a patient
who suffered complications from osteomalacia that had
gone unrecognized for some time, and report a very high
prevalence of vitamin D deficiency amongst inpatients on
a psychiatric rehabilitation ward. We review the basics of
vitamin D metabolism, and the causes and clinical fea-
tures of osteomalacia. We offer practical suggestions for
psychiatrists for the treatment of simple vitamin D defi-
ciency, which in the United Kingdom is presently compli-
cated by problems affecting the supply of high-dose
vitamin D.
Methods
We provide a case report of a patient with severe vitamin
D deficiency, illustrating its clinical presentation. Her case
is unusual because she has been an inpatient for more
than 35 years, meaning that her diet and activity have in
large part been under hospital supervision, and that she
has had frequent surveillance of serum biochemical indi-
ces relevant to osteomalacia. We measured the vitamin D
status (serum 25-hydroxyvitamin D level) in April–May
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iatric rehabilitation ward (n = 12).
Serum 25-hydroxyvitamin D was measured by radioim-
munoassay (Immunodiagnostic Systems Ltd, Boldon,
UK) in a UK Clinical Pathology Accreditation (CPA)
approved laboratory [2]. The assay under-recovers plant-
derived 25-hydroxyvitamin D2 but not 25-hydroxyvita-
min D3 (for assay specifications see [2] and the manufac-
turer's data at http://www.idsplc.com/z_includes/
z_assets/asset_file.php?id=8843). Local control values
were derived from repeated measurements over one year
of 25-hydroxyvitamin D in 96 healthy Caucasian East
Anglian adults of mean age 69 ± 2.9 years (see [2]). All
analyses were conducted using R version 2.7.0 [3].
Results
Case
We report on a 75-year-old Caucasian woman, admitted
in 1972 aged 39 for schizophrenia. She has been an infor-
mal inpatient since then. In her later years, her medical
history includes atrial fibrillation, recurrent pneumonia,
pulmonary fibrosis, small-vessel cerebrovascular disease,
gallstones, and lupus anticoagulant without antinuclear
antibody. Her regular drug treatment comprised clozap-
ine, digoxin, furosemide, simvastatin, senna, lactulose,
and zolpidem. She was on no calcium or vitamin D sup-
plements. Aspirin had recently been replaced with warfa-
rin, which was stopped shortly afterwards following the
development of iron-deficiency anaemia. She was inde-
pendently mobile and a smoker.
We investigated her for a mildly but persistently elevated
alkaline phosphatase, with intermittently low phosphate
and calcium (Figure 1). Her albumin, bilirubin, alanine
aminotransferase (ALT), and renal function were normal.
Bone and liver isoforms of alkaline phosphatase were not
measured. The diagnosis of osteomalacia was confirmed
when in April 2008 her serum 25-hydroxyvitamin D level
was found to be 10.5 nM, representing severe deficiency
(Figure 2A). Coeliac serology was negative. She was com-
menced on calcium and vitamin D supplementation but
fell and suffered a subcapital fracture of her femoral neck
later that night, requiring hemiarthroplasty, subsequently
complicated by pneumonia, wound infection, urinary
tract infection, sepsis, recurrent hemiarthroplasty disloca-
tion and prosthesis infection requiring excision arthro-
plasty.
Prevalence of vitamin D deficiency
All patients examined were Caucasian. Their mean age
was 71.4 years. Eleven (92%) had suboptimal levels and
10 (83%) had frank deficiency (Figure 2B, C). Three
patients were on vitamin D supplements as multivita-
Serum alkaline phosphatase (•), corrected calcium (▲), and phosphate () for the index patientFig re 1
Serum alkaline phosphatase (•), corrected calcium (▲), and phosphate () for the index patient. Horizontal lines 
show upper and lower limits of normal ranges for all variables. Alkaline phosphatase increased over time (linear component, r2 
= 0.46, F1,28 = 23.9, p = 0.000037).
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predictor of vitamin D status was supplementation (sig-
nificant effect of supplementation on 25-hydroxyvitamin
D levels, F1,7 = 33.7, p = 0.00066, in a linear model using
age and admission time as continuous predictors, and
supplementation and sex as two-level factors, with no
interactions, and assessing the contribution of each pre-
dictor over and above that of all others). As supplementa-
tion was infrequent and heterogeneous, we analysed only
the non-supplemented group further. Of those nine not
on vitamin D supplements, 100% had vitamin D defi-
ciency. There was no effect of age, sex, or duration of
admission in this subgroup (Fs < 1, NS).
In comparison to the historical control group, those
patients not on supplements not only had serum 25-
hydroxyvitamin D levels significantly below the seasonal
control mean, but significantly below the 2.5th centile for
the winter trough (t8 = 3.07, p = 0.015).
Discussion
Vitamin D deficiency and osteomalacia
Osteomalacia is defective mineralization of bone matrix
(osteoid) and results from vitamin D deficiency [4,5].
Vitamin D is required for effective calcium absorption. It
is absorbed from the gut as ergocalciferol (vitamin D2) or
colecalciferol (cholecalciferol; vitamin D3), or made from
7-dehydrocholesterol in the skin as colecalciferol. Both
vitamin D2 and vitamin D3, collectively known as vitamin
D, are stored in fat. Circulating vitamin D is then hydrox-
ylated in the liver to 25-hydroxyvitamin D, and again in
the kidney (under feedback control) to 1,25-dihydroxyvi-
tamin D, the active form [5]. Vitamin D status is best
assayed by measuring serum 25-hydroxyvitamin D [1].
Few foods contain significant vitamin D. The principal
dietary sources are oily fish, fortified products, and dietary
supplements [1]. In the UK, vitamin D fortification is
mandatory only for margarine, and milk is not usually
fortified [6]. Vitamin D deficiency in the UK is very com-
mon, with 12% of Caucasian and 33% of Asian outpa-
tients having levels < 25 nM at the end of summer [7], and
87% of middle-aged Caucasians having levels < 75 nM in
Serum 25-hydroxyvitamin D levels in historical controls and psychiatric inpatientsFig re 2
Serum 25-hydroxyvitamin D levels in historical controls and psychiatric inpatients. (A) Normal values for healthy 
East Anglian adults of mean age 69 years [2]. Circles show means; bars indicate 95% intervals. Solid and dotted horizontal lines 
indicate suggested thresholds for deficiency and sufficiency, respectively [1]; toxicity is unlikely with levels below 374 nM [1,27]. 
(B, C) Serum 25-hydroxyvitamin D levels of inpatients in the current survey (taken in April–May) shown by age, sex, duration 
of admission, and supplementation status. Filled symbols show patients on vitamin D supplementation, with label showing sup-
plement amount in international units (IU) per day. Open symbols show those not supplemented. Circles show females; dia-
monds show males. Solid and dotted lines indicate thresholds for deficiency and sufficiency as before.
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older East Anglian adults [2]. The prevalence of deficiency
increases with age (as skin 7-dehydrocholesterol levels
decrease), skin pigment, and obesity [1,6,7]. Lack is usu-
ally due to dietary deficiency combined with lack of suffi-
cient sunlight-dependent synthesis in the skin. More
rarely, deficiency may be due to malabsorption; liver dis-
ease; renal disease; some therapeutic drugs; hyperparathy-
roidism, hyperthyroidism, and granulomatous diseases
(through increased vitamin D metabolism); and other
rarer causes [1,4,5].
Osteomalacia causes bone pain and tenderness, skeletal
deformity, and proximal muscle weakness, and predis-
poses to fracture [4]. Osteoporosis commonly co-exists,
and osteomalacia exacerbates osteoporosis [1]. Addition-
ally, vitamin D deficiency is associated with an increased
risk of cancer, type 1 and type 2 diabetes mellitus, multi-
ple sclerosis, Crohn's disease, hypertension, heart failure,
and airways disease [1]. It is also associated with schizo-
phrenia, perhaps via developmental vitamin D deficiency
[8,9], and with depression, with some evidence for a ther-
apeutic effect of vitamin D [10-12]. In osteomalacia, cal-
cium and phosphate are low or normal, urinary calcium is
low, and the alkaline phosphatase is typically raised as the
disease progresses [4].
Patients with psychotic illnesses are at additional risk of
osteoporosis, at least in part because many antipsychotic
drugs cause hyperprolactinaemia that can lead to a reduc-
tion in bone mineral density [13,14]. Other endocrine
mechanisms may also play a role in the high prevalence of
osteoporosis in schizophrenia [15,16].
Causes in this case
In the index case, osteomalacia was secondary jointly to
inadequate dietary vitamin D intake and inadequate ultra-
violet B exposure, even though she liked to be outdoors in
good weather. There was likely concomitant osteoporosis.
As our patient habitually ate the hospital food provided
without rejection, the duration of her inpatient stay indi-
cates that the hospital's food did not provide sufficient
vitamin D over a prolonged period to prevent deficiency
or perhaps to correct pre-existing deficiency. The diet cur-
rently provided is low in oily fish, and efforts are under-
way to improve it.
High prevalence of vitamin D deficiency
This was a small survey. Nonetheless, it is clear that this
population is at extremely high risk of vitamin D defi-
ciency, and in our results this was independent of the
duration of admission. Vitamin D deficiency is common
in the UK [6,7], yet the prevalence and degree of vitamin
D deficiency in our study population was significantly
higher than in healthy historical controls of a similar age.
Suggestions
Osteomalacia must always be considered in the differen-
tial diagnosis of a raised alkaline phosphatase. We suggest
that all hospitals should undergo regular review by a die-
tician to ensure adequate vitamin D is provided or supple-
mentation is in place; this is particularly important for
environments where patients are resident for prolonged
periods, such as long-stay psychiatric units. Psychiatrists
should ensure vitamin D supplementation is adequate.
Vitamin D level screening is worthwhile in high-risk pop-
ulations, and supplementation can reduce the risk of frac-
ture in the elderly, and a range of other major diseases [1].
In addition to effects on bone metabolism, there is evi-
dence from meta-analysis of randomized controlled trials
that vitamin D supplementation can reduce the risk of
falls in the elderly [17,18]; the mechanism may be via
lower limb muscle strength and improved balance [19-
21].
Prevention and treatment of simple deficiency
A daily intake of 800–1,000 international units (IU) (20–
25 μg) is probably desirable to prevent deficiency in
adults without other major risk factors; achieving this may
require widespread supplementation [1]. More may be
required in the obese, in pregnant and lactating women,
and if other risk factors for deficiency exist [1]. The Euro-
pean Community Recommended Daily Amount (EC
RDA) is only 200 IU [22], which is inadequate [1]. Vita-
min D2 and vitamin D3 are both effective supplements
[23]; suggestions for maintenance supplementation are
shown in Table 1. Treatment of established deficiency
requires higher doses of vitamin D. One strategy for treat-
ing deficiency due to dietary or sunlight deficiency is to
give 50,000 IU of ergocalciferol orally once weekly for 8
weeks, repeating for another 8 weeks if vitamin D levels
remain < 75 nM [1]. Another simple regimen is to give
ergocalciferol 10,000 IU orally once daily during this
treatment period [24], or intramuscular colecalciferol
300,000 IU monthly [24]. Vitamin D deficiency second-
ary to more complex causes or when renal failure is
present may need still higher doses or, if vitamin D
metabolism is significantly impaired, calcitriol (1,25-
hydroxycolecalciferol) [25]. The need for simultaneous
calcium supplementation, to achieve a total daily intake
of the order of 1,000–1,200 mg, should always be consid-
ered [26].
Risk of vitamin D toxicity
Vitamin D toxicity is unlikely to occur with serum 25-
hydroxyvitamin D levels below 374 nM unless there is
hypersensitivity to vitamin D (e.g. hyperparathyroidism,
granulomatous diseases) [1,27]. Vitamin D toxicity is
caused by hypercalcaemia [27] and when very high doses
of vitamin D are used or if there is renal impairment,
plasma calcium monitoring is required weekly and if nau-Page 4 of 7
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BMC Research Notes 2009, 2:82 http://www.biomedcentral.com/1756-0500/2/82Table 1: Examples of regimes for treating simple vitamin D deficiency (deficiency secondary to inadequate sunlight exposure or 
dietary intake), and maintenance supplementation.
Regime Approximate daily dose Comments and disadvantages
Treatment of vitamin D deficiency
ergocalciferol 250 μg (10,000 IU) once daily 10,000 IU vitamin D Supply problem in the UK.
ergocalciferol 1.25 mg (50,000 IU) once weekly 7,000 IU vitamin D Supply problem in the UK.
intramuscular ergocalciferol or colecalciferol 
7.5 mg (300,000 IU) monthly
10,000 IU vitamin D Injection may be unpopular. Supply problem in 
the UK.
paediatric ergocalciferol solution (3,000 IU/ml), 
3 ml daily
9,000 IU vitamin D Special supply arrangements may be required. 
Excipients may include peanut oil.
colecalciferol 500 μg (20,000 IU) 3–4 times per 
week
8,600–11,400 IU vitamin D Available from overseas suppliers.
colecalciferol liquid, e.g. 2,000 IU/ml, 5 ml daily 10,000 IU vitamin D Custom strengths available as 'special' orders in 
the UK.
commercial 'high strength' (25 μg; 1,000 IU) 
colecalciferol, two tablets twice daily
4,000 IU vitamin D Available from high street health food suppliers 
including online.
colecalciferol 25 μg (1,000 IU), two tablets 
twice daily, plus compound calcium (500 mg) 
with ergocalciferol or colecalciferol (400 IU), 
one tablet twice daily
4,800 IU vitamin D
1,000 mg calcium
Includes sufficient calcium to ensure adequate 
total intake (though calcium supplements may 
have low palatability).
compound calcium (500 mg) with ergocalciferol 
or colecalciferol (400 IU), two tablets twice 
daily, plus generic multivitamins (including 300 
IU vitamin D), two capsules twice daily
2,800 IU vitamin D
2,000 mg calcium
10,000 IU vitamin A (3,000 μg RE)
60 mg ascorbic acid
30 mg nicotinamide
2 mg riboflavin
4 mg thiamine
Not ideal. Vitamin D dose lower than 
recommended treatment regimens. Many 
tablets required. Calcium content gives poor 
palatability and may cause gastrointestinal side 
effects in a few patients [37]. The vitamin A 
dose may be close to a prudent threshold for 
teratogenicity, and exceeds the maximum dose 
recommended for long-term use (1,500 μg RE/
day); higher doses are associated with 
increased risk of hip fracture [37]. No other 
component is likely to produce toxicity at this 
dose [37].
1-hydroxylated derivatives of vitamin D 
(e.g. alfacalcidol, dihydrotachysterol, calcitriol)
-- Not recommended. Does not treat vitamin D 
deficiency. Higher potential for toxicity. 
Greater need for monitoring. Few reasons to 
use, unless severe renal disease or 
hypocalcaemia [31-34].
Maintenance supplementation 
(examples)
ergocalciferol 1.25 mg (50,000 IU) every 2–4 
weeks or monthly
1,640–3,570 IU vitamin D Supply problem in the UK.
colecalciferol 25 μg (1,000 IU) daily 1,000 IU vitamin D --
compound calcium (500 mg) with ergocalciferol 
or colecalciferol (400 IU), one tablet twice daily
800 IU vitamin D
1,000 mg calcium
Includes sufficient calcium to ensure adequate 
total intake.
Additional non-pharmacological optionsPage 5 of 7
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ics also increase the risk of hypercalcaemia [25]. However,
doses of 10,000 IU per day are equivalent to what may be
obtained from sunlight and are extremely unlikely to
cause toxicity [1,27,28].
Treatment options given vitamin D supply problems in the 
UK
A significant practical problem is that there is currently a
supply failure of high-dose oral and injectable ergocalcif-
erol in the UK [29]. Colecalciferol is not listed in a high-
dose (> 800 IU/day) preparation in the British National
Formulary [25]. The 1-hydroxylated derivatives of vitamin
D available (alfacalcidol, dihydrotachysterol, and calci-
triol) are much more potent, escape a key metabolic regu-
latory step, and have a rapid onset and offset of action as
they are not stored in significant quantities in fat [1,5].
Thus, although they are biologically active whilst they are
being given, they do not replenish bodily stores of vitamin
D [30]. They are also more likely to cause hypercalcaemia,
and require calcium monitoring. They are not recom-
mended for treating simple vitamin D deficiency without
hypocalcaemia [31-34]. Alternatives strategies for restora-
tion of normal bodily stores therefore include high doses
of compound preparations [35], paediatric formulations,
and commercial supplements. Practical approaches to this
problem are outlined in Table 1.
Conclusion
This study illustrates the high prevalence of vitamin D
deficiency in an old-age psychiatric rehabilitation unit,
something also observed recently but to a lesser extent in
a younger psychiatric inpatient population [36]. Vitamin
D deficiency is extremely common, especially in countries
far from the equator and where food supplementation is
not widespread. It predisposes to a wide range of serious
diseases. Key points are that (1) the serum 25-hydroxyvi-
tamin D level is the best measure of vitamin D status; (2)
many patients in geriatric psychiatry units will need treat-
ment for vitamin D deficiency, and most need mainte-
nance supplementation; and (3) supply problems
currently complicate the prescription of high-dose vita-
min D in the United Kingdom.
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